Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer
Lurbinectedin demonstrated comparable real-world effectiveness with OST with a favorable safety profile; however, these findings are limited by small sample size.
Authors
- Apar Kishor Ganti (ORCID: https://orcid.org/0000-0003-3724-2671)
- Badri Rengarajan
- Victoria Allan (ORCID: https://orcid.org/0000-0002-3284-8896)
- Elizabeth M. Poole (ORCID: https://orcid.org/0000-0002-4680-4587)
- Adina Estrin (ORCID: https://orcid.org/0000-0001-8866-2911)
- Xiaozhou Fan (ORCID: https://orcid.org/0000-0002-6841-6606)
- Yanyan Cao (ORCID: https://orcid.org/0009-0002-4735-0668)
- Wenyan Li (ORCID: https://orcid.org/0000-0003-1861-6383)
- Patricia Prince (ORCID: https://orcid.org/0000-0002-0705-6942)
- Ralph B. D’Agostino (ORCID: https://orcid.org/0000-0003-3957-0046)
- Nileesa Gautam
- Anne Boccuti
Institutions
- Jazz Pharmaceuticals (United States) (US)
- Aetion (United States) (US)
- Jazz Pharmaceuticals (Italy) (IT)
- Engineering Information Foundation (US)
- Jazz Pharmaceuticals (France) (FR)
- VA Nebraska Western Iowa Health Care System (US)
- Wake Forest University (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1080/14796694.2025.2499441
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Jazz Pharmaceuticals